Brief Title
Indirect Comparison Topotecan Cervical Carcinoma
Official Title
Indirect Comparison of the Efficacy Between Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix
Brief Summary
Indirect comparisons were performed using data from GOG-0179 versus GOG-0169 to permit comparison of topotecan in combination with cisplatin versus cisplatin plus paclitaxel via the common comparator of cisplatin monotherapy. Both GOG-0179 and GOG-0169 were conducted in patients with stage IVB, recurrent or persistent carcinoma of the cervix, but there were some differences between the respective study populations. Patients with prior chemotherapy were eligible for GOG-0179 but ineligible for GOG-0169 (except when chemotherapy was used for radiation sensitisation). Fewer patients had received chemotherapy as a radiosensitiser in GOG-0169 (27%) than in GOG-0179 (~60%) and these patients were unevenly distributed between treatment arms in GOG-0169. In addition, the proportion of patients receiving cisplatin as a radiosensitiser in GOG-0169 is unknown. For these reasons, there are limitations associated with the indirect meta-analysis.
Study Type
Observational
Primary Outcome
Overall survival
Condition
Cervical Intraepithelial Neoplasia
Intervention
cisplatin
Study Arms / Comparison Groups
cisplatin
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
1
Start Date
June 2009
Completion Date
July 2009
Primary Completion Date
July 2009
Eligibility Criteria
Inclusion Criteria: - randomised clinical trials, or systematic reviews and meta-analyses - treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease Exclusion Criteria: - None
Gender
Female
Ages
21 Years - N/A
Accepts Healthy Volunteers
No
Contacts
GSK Clinical Trials, ,
Administrative Informations
NCT ID
NCT01345279
Organization ID
114016
Responsible Party
Sponsor
Study Sponsor
GlaxoSmithKline
Study Sponsor
GSK Clinical Trials, Study Director, GlaxoSmithKline
Verification Date
May 2017